Rab4 Antibody: ATTO 390 SPC-141D-A390 from StressMarq Biosciences Inc

Product Specs
ItemRab4 Antibody: ATTO 390
CompanyStressMarq Biosciences Inc
Price $306.00Supplier Page View Company Product Page
Catalog NumberSPC-141D-A390
Quantity100 µl
ApplicationsWB, IHC, ICC/IF
Concentration1 mg/ml
Conjugate/TagATTO 390
FormatRabbit antiserum
ReactivityHuman, Mouse, Rat
TargetRab4
HostRabbit
ImmunogenC-terminal peptide from human Rab4
NCBI Full Gene NameRAB4A, member RAS oncogene family
NCBI Gene AliasesHRES1, HRES-1/RAB4, HRES-1, RAB4
ClonalityPolyclonal
Research AreaCell Signaling, Tags and Cell Markers, Organelle Markers, Neuroscience, Cell Markers, Neuron Markers, Presynaptic Markers

117-1537 Hillside Ave.

Victoria, British Columbia V8T 4Y2

Canada

Phone: +1-250-294-9065
Fax: 1-250-294-9025

Email: info@stressmarq.com

(1) Targeting the Negative Feedback of Adenosine-A2AR Metabolic Pathway by a Tailored Nanoinhibitor for Photothermal ImmunotherapyAdvanced science (Weinheim, Baden-Wurttemberg, Germany)May 1, 2022Liu Y, Liu Y, Xu D, Zang J, Zheng X, Zhao Y, Li Y, He R, Ruan S, Dong H, et al.

(2) Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanomaBioelectrochemistry (Amsterdam, Netherlands)February 1, 2018Ursic K, Kos S, Kamensek U, Cemazar M, Scancar J, Bucek S, Kranjc S, Staresinic B, Sersa G.

(3) Calreticulin is a novel independent prognostic factor for oral squamous cell carcinomaOncology lettersJune 1, 2017Harada K, Takenawa T, Ferdous T, Kuramitsu Y, Ueyama Y.

(4) HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly SitesJournal of virologyAugust 1, 2016Pujol FM, Laketa V, Schmidt F, Mukenhirn M, Müller B, Boulant S, Grimm D, Keppler OT, Fackler OT.

(5) Nef proteins of epidemic HIV-1 group O strains antagonize human tetherinCell host & microbeNovember 12, 2014Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, Usmani SM, Sauter D, Joas S, Hotter D, et al.

(10) Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinomaCancer immunology, immunotherapy : CIIMay 1, 2010Tongu M, Harashima N, Yamada T, Harada T, Harada M.

Rab4 Antibody: ATTO 390